Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has granted Breakthrough Therapy designation to GLM101, an investigational treatment for PMM2-CDG — a rare genetic disorder that causes cerebellar ataxia and developmental delays. GLM101 works by delivering a key enzyme building block directly into cells to correct the underlying deficiency. Pivotal trial results are expected in late 2026.
The FDA has awarded Breakthrough Therapy designation to GLM101, developed by Glycomine, for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) — a rare, inherited metabolic disease with no currently approved treatments. The condition stems from mutations in the PMM2 gene, leading to an enzyme deficiency that disrupts glycosylation and affects multiple organ systems, with neurological symptoms like cerebellar ataxia and developmental delay being the most prominent.
GLM101 takes a targeted approach by delivering mannose-1-phosphate directly into cells, effectively compensating for the missing enzyme activity. The therapy is now being evaluated in the phase 2b POLAR trial — a randomized, double-blind, placebo-controlled study enrolling 43 pediatric and adult patients.
By the Numbers:
Why it matters: PMM2-CDG is a debilitating rare disease with no approved therapies, leaving patients with limited options. The Breakthrough Therapy designation accelerates GLM101's development pathway and enables more frequent FDA collaboration — bringing hope closer for a patient population that has long been underserved.
